The impact of implementing a non-invasive preimplantation genetic testing for aneuploidies (niPGT-A) embryo culture protocol on embryo viability and clinical outcomes.

Autor:	Sakkas D; Boston IVF R&D Department, Boston IVF-IVIRMA Global Research Alliance, Waltham, MA, USA., Navarro-Sánchez L; R&D Department, Igenomix, Paterna, Valencia, Spain., Ardestani G; Boston IVF R&D Department, Boston IVF-IVIRMA Global Research Alliance, Waltham, MA, USA., Barroso G; IVF Clinical Department, Escuela Superior de Medicina Instituto Politécnico Nacional y Centro de Reproducción Arcos S.C. NASCERE, CDMX, Mexico., Bisioli C; Department of Reproductive Genetics, Pregna Medicina Reproductiva, Buenos Aires, Argentina., Boynukalin K; Clinical Department, Bahçeci Fertility, Istanbul, Turkey., Cimadomo D; Science & Research, GENERA Center for Reproductive Medicine, Clinica Valle Giulia, Rome, Italy., Frantz N; Embryology Department, Nilo Frantz Reproductive Medicine, Porto Alegre, Brazil., Kopcow L; Department of Reproductive Genetics, Pregna Medicina Reproductiva, Buenos Aires, Argentina., Andrade GM; Embryology Department, Nilo Frantz Reproductive Medicine, Porto Alegre, Brazil., Ozturk B; Clinical Department, Bahçeci Fertility, Istanbul, Turkey., Rienzi L; Science & Research, GENERA Center for Reproductive Medicine, Clinica Valle Giulia, Rome, Italy., Weiser A; IVF Clinical Department, Escuela Superior de Medicina Instituto Politécnico Nacional y Centro de Reproducción Arcos S.C. NASCERE, CDMX, Mexico., Valbuena D; R&D Department, Igenomix, Paterna, Valencia, Spain., Simón C; Department of Pediatrics, Obstetrics and Gynecology, University of Valencia, INCLIVA, Valencia, Spain.; Research & Medical Department, Carlos Simon Foundation, INCLIVA Health Research Institute, Valencia, Spain.; Department of Obstetrics and Gynecology, BIDMC, Harvard University, Boston, MA, USA., Rubio C; R&D Department, Igenomix, Paterna, Valencia, Spain.
Jazyk:	angličtina
Zdroj:	Human reproduction (Oxford, England) [Hum Reprod] 2024 Sep 01; Vol. 39 (9), pp. 1952-1959.
DOI:	10.1093/humrep/deae156
Abstrakt:	Study Question: Are modifications in the embryo culture protocol needed to perform non-invasive preimplantation genetic testing for aneuploidies (niPGT-A) affecting clinical reproductive outcomes, including blastocyst development and pregnancy outcomes? Summary Answer: The implementation of an embryo culture protocol to accommodate niPGT-A has no impact on blastocyst viability or pregnancy outcomes. What Is Known Already: The recent identification of embryo cell-free (cf) DNA in spent blastocyst media has created the possibility of simplifying PGT-A. Concerns, however, have arisen at two levels. First, the representativeness of that cfDNA to the real ploidy status of the embryo. Second, the logistical changes that need to be implemented by the IVF laboratory when performing niPGT-A and their effect on reproductive outcomes. Concordance rates of niPGT-A to invasive PGT-A have gradually improved; however, the impact of culture protocol changes is not as well understood. Study Design, Size, Duration: As part of a trial examining concordance rates of niPGT-A versus invasive PGT-A, the IVF clinics implemented a specific niPGT-A embryo culture protocol. Briefly, this involved initial culture of fertilized oocytes following each laboratory standard routine up to Day 4. On Day 4, embryos were washed and cultured individually in 10 μl of fresh media. On Day 6 or 7, blastocysts were then biopsied, vitrified, and media collected for the niPGT-A analysis. Six IVF clinics from the previously mentioned trial were enrolled in this analysis. In the concordance trial, Clinic A cultured all embryos (97 cycles and 355 embryos) up to Day 6 or 7, whereas in the remaining clinics (B-F) (379 cycles), nearly a quarter of all the blastocysts (231/985: 23.5%) were biopsied on Day 5, with the remaining blastocysts following the niPGT-A protocol (754/985: 76.5%). During the same period (April 2018-December 2020), the IVF clinics also performed standard invasive PGT-A, which involved culture of embryos up to Days 5, 6, or 7 when blastocysts were biopsied and vitrified. Participants/materials, Setting, Methods: In total, 428 (476 cycles) patients were in the niPGT-A study group. Embryos from 1392 patients underwent the standard PGT-A culture protocol and formed the control group. Clinical information was obtained and analyzed from all the patients. Statistical comparisons were performed between the study and the control groups according to the day of biopsy. Main Results and the Role of Chance: The mean age, number of oocytes, fertilization rates, and number of blastocysts biopsied were not significantly different for the study and the control group. Regarding the overall pregnancy outcomes, no significant effect was observed on clinical pregnancy rate, miscarriage rate, or ongoing pregnancy rate (≥12 weeks) in the study group compared to the control group when stratified by day of biopsy. Limitations, Reasons for Caution: The limitations are intrinsic to the retrospective nature of the study, and to the fact that the study was conducted in invasive PGT-A patients and not specifically using niPGT-A cases. Wider Implications of the Findings: This study shows that modifying current IVF laboratory protocols to adopt niPGT-A has no impact on the number of blastocysts available for transfer and overall clinical outcomes of transferred embryos. Whether removal of the invasive biopsy step leads to further improvements in pregnancy rates awaits further studies. Study Funding/competing Interest(s): This study was funded by Igenomix. C.R., L.N.-S., and D.V. are employees of Igenomix. D.S. was on the Scientific Advisory Board of Igenomix during the study. Trial Registration Number: ClinicalTrials.gov (NCT03520933). (© The Author(s) 2024. Published by Oxford University Press on behalf of European Society of Human Reproduction and Embryology. All rights reserved. For permissions, please email: journals.permissions@oup.com.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu